ClinicalTrials.gg
RecruitingNCT07649031Updated Jul 2, 2026

MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients

An observational study in Fanconi Anemia, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of Minnesota · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients.

02

Conditions studied

  • Fanconi Anemia

Browse trials for

03

In context

Fanconi Anemia

95 studies on the registry are indexed under Fanconi Anemia; 20 are open to participants now.

This study's planned enrollment of 80 is below the median of 94 across 24 observational studies indexed under Fanconi Anemia.

Browse Fanconi Anemia studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.

Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Fanconi anemia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of Fanconi Anemia who are willing to participate and willing to have MRIs
  • Willing to provide

Exclusion criteria

Exclusion Criteria:

  • Patient without diagnosis of FA
  • Patients with FA who are under the age of 18
  • Unable to tolerate any MRI due to claustrophobia
  • Any for the MRI
  • Unable to provide or comply with the study protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • FA patients with a history of HNSCC

    This group will receive both mMRI and ddMRI, with an exam, every 3-4 months for 2 years (up to 16 scan (+exam) visits).

    Diagnostic Test: MRIs

  • FA patients with no history of HNSCC

    This group will receive two scans each of mMRI and ddMRI, with an exam, one year apart (up to 4 scan (+exam) visits).

    Diagnostic Test: MRIs

Interventions

  • Diagnostic testMRIs

    mMRI and ddMRI

06

What researchers measure

Primary outcomes

  1. sensitivity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.

    Proportion of positive lesions correctly diagnosed

    Time frame: Immediately after MRI

  2. specificity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.

    Proportion of negative lesions correctly diagnosed

    Time frame: Immediately after MRI

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2030, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Jun 23, 2026
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07649031
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Jun 23, 2026
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Jul 2, 2026

Study contacts

Carla Campbell, BS
Contact
camp2757@umn.edu
612-625-6976
Rachel Uppgaard
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion